Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies
Abstract
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) and VITT-like syndromes are emerging causes of severe thrombocytopenia and thrombosis associated with immunoglobulin G (IgG) antibodies targeting platelet factor 4 (PF4). These syndromes are characterized by more frequent and severe thrombosis than heparin-induced thrombocytopenia (HIT), which is typically caused by antibodies targeting heparin-modified PF4 (anti-PF4/H). In this study, we compared the intrinsic prothrombotic properties of IgG anti-PF4 and anti-PF4/H to identify mechanisms that may contribute to the severity of VITT and VITT-like syndromes. Using the monoclonal IgG1 antibodies 1E12 (anti-PF4) and 5B9 (anti-PF4/H), we showed that IgG anti-PF4 exhibited an increased propensity to induce the formation of fibrin-rich platelet-leukocytes aggregates in a microfluidic model of whole-blood (WB) thrombosis. This phenomenon was related to a strong potentiation of thrombin generation in plasma by 1E12, but not by 5B9, and occurred only in the presence of platelets and coagulation factors V and XI. We also demonstrated a substantially faster and stronger ability of 1E12, compared with 5B9, to activate platelets using the serotonin release assay and confirmed these findings using human VITT and HIT samples. Furthermore, 1E12 was more likely than 5B9 to induce procoagulant platelets (CD62P+/phosphatidylserine+) in platelet-rich plasma (PRP) and to produce procoagulant microvesicles in WB and PRP. In conclusion, platelets are activated faster and exhibit more procoagulant activity in response to anti-PF4 than anti-PF4/H, which may contribute to the severity of VITT and VITT-like syndromes.
Related
- CO016 | PLATELET HYPER-REACTIVITY AND PROCOAGULANT PHENOTYPE IN ESSENTIAL THROMBOCYTHEMIA: INSIGHTS FROM ADVANCED PLATELET FUNCTION TESTING
- PO027 | IGFBP-6 REGULATES PLATELET PROCOAGULANT ACTIVITY AT THE INTERFACE BETWEEN INFLAMMATION AND COAGULATION
- Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assays
- CO098 | ANTI-β2GPI AND ANTI-PS/PT ANTIBODIES, AND THEIR COMBINATION, EXERT A DISTINCT PLATELET ACTIVATION PROFILE
- The ability of SAMHD1-deficient monocytes to trigger the Type I IFN response depends on cGAS and mitochondrial DNA
BibTeX
@article{augros2026antipf4,
title = {{Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies}},
author = {Johanna Augros and Jérôme Rollin and Julie Benzakine and Estelle Archer and Sandra Billy and Annabelle Dupont and Mélanie Daniel and Yves Gruel and Claire Pouplard and Caroline Vayne},
journal = {Blood Advances},
year = {2026},
month = oct,
doi = {10.1182/bloodadvances.2026020237},
url = {https://hal.science/hal-05848970v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Anti-PF4 antibodies trigger a faster and stronger platelet procoagulant response than anti-heparin/PF4 antibodies
AU - Johanna Augros
AU - Jérôme Rollin
AU - Julie Benzakine
AU - Estelle Archer
AU - Sandra Billy
AU - Annabelle Dupont
AU - Mélanie Daniel
AU - Yves Gruel
AU - Claire Pouplard
AU - Caroline Vayne
PY - 2026
DA - 2026/10/27
JO - Blood Advances
DO - 10.1182/bloodadvances.2026020237
UR - https://hal.science/hal-05848970v1
AB - Vaccine-induced immune thrombocytopenia and thrombosis (VITT) and VITT-like syndromes are emerging causes of severe thrombocytopenia and thrombosis associated with immunoglobulin G (IgG) antibodies targeting platelet factor 4 (PF4). These syndromes are characterized by more frequent and severe thrombosis than heparin-induced thrombocytopenia (HIT), which is typically caused by antibodies targeting heparin-modified PF4 (anti-PF4/H). In this study, we compared the intrinsic prothrombotic properties of IgG anti-PF4 and anti-PF4/H to identify mechanisms that may contribute to the severity of VITT and VITT-like syndromes. Using the monoclonal IgG1 antibodies 1E12 (anti-PF4) and 5B9 (anti-PF4/H), we showed that IgG anti-PF4 exhibited an increased propensity to induce the formation of fibrin-rich platelet-leukocytes aggregates in a microfluidic model of whole-blood (WB) thrombosis. This phenomenon was related to a strong potentiation of thrombin generation in plasma by 1E12, but not by 5B9, and occurred only in the presence of platelets and coagulation factors V and XI. We also demonstrated a substantially faster and stronger ability of 1E12, compared with 5B9, to activate platelets using the serotonin release assay and confirmed these findings using human VITT and HIT samples. Furthermore, 1E12 was more likely than 5B9 to induce procoagulant platelets (CD62P+/phosphatidylserine+) in platelet-rich plasma (PRP) and to produce procoagulant microvesicles in WB and PRP. In conclusion, platelets are activated faster and exhibit more procoagulant activity in response to anti-PF4 than anti-PF4/H, which may contribute to the severity of VITT and VITT-like syndromes.
SN - 2473-9529
SN - 2473-9537
ER -